{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-25-000037","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.803788+00:00","generated_at":"2026-05-17T20:51:12.726788+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amneal Q2: rev $725M (+3%), adj EBITDA $184M (+13%), raises FY25 guidance, refi debt","bullets":["Q2 net revenue $725M, up 3% YoY; GAAP net income $22M vs $6M in Q2 2024.","Adjusted EBITDA $184M (+13%); adjusted diluted EPS $0.25 (+56% from $0.16).","Specialty revenue +23% driven by CREXONT, RYTARY, UNITHROID; Affordable Medicines +1%.","Raising full-year 2025 guidance; completed oversubscribed debt refinancing extending maturities to 2032.","FDA approved Brekiya autoinjector for migraine; strong CREXONT Parkinson's uptake."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-25-000037","json":"https://secwatch.observer/filing/0001723128-25-000037.json","markdown":"https://secwatch.observer/filing/0001723128-25-000037.md","text":"https://secwatch.observer/filing/0001723128-25-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312825000037/0001723128-25-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312825000037/amrx-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:51:12.726788+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}